Henry: Cancer Management in Small Animal Practice

Chapter 16: Immunotherapy


  1. Bergman PJ: Biologic response modification. In Rosenthal RC (ed): Veterinary oncology secrets. Philadelphia, 2001, Hanley & Belfus, 79-82.
  2. Reilly RT, Emens LA, Jaffee EM: Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr Opin Investig Drugs 2(1):133, 2001. Medline abstracts
  3. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy, Nat Immunol 2(4):293, 2001. Medline abstracts
  4. Wallace ME, Smyth MJ: The role of natural killer cells in tumor control—effectors and regulators of adaptive immunity, Springer Semin Immunopathol 27(1):49, 2005. Medline abstracts
  5. Catchpole B, Gould SM, Kellett-Gregory LM, et al: Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma, J Small Anim Pract 43(10):464, 2002. Medline abstracts
  6. Zagury D, Gallo RC: Anti-cytokine Ab immune therapy: present status and perspectives, Drug Discov Today 9(2):72, 2004. Medline abstracts
  7. Morse MA, Mosca PJ, Clay TM, et al: Dendritic cell maturation in active immunotherapy strategies, Expert Opin Biol Ther 2(1):35, 2002. Medline abstracts
  8. Yamaguchi T, Sakaguchi S: Regulatory T-cells in immune surveillance and treatment of cancer, Semin Cancer Biol 16(2):115, 2006. Medline abstracts
  9. Richardson MA, Ramirez T, Russell NC, et al: Coley toxins immunotherapy: a retrospective review, Altern Ther Health Med 5(3):42, 1999. Medline abstracts
  10. Parodi AL, Misdorp W, Mialot M, et al: Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy, Cancer Immunol Immunother 15(3):172, 1983. Medline abstracts
  11. Klein WR, Rutten VP, Steerenberg PA, et al: The present status of BCG treatment in veterinary practice, In Vivo 5(6):605, 1991. Medline abstracts
  12. Hess AD, Catchatourian R, Zander AR, et al: Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors, Cancer Res 37(11):3990, 1977. Medline abstracts
  13. Bostock DE, Gorman NT: Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumour, Eur J Cancer 14(8):879, 1978. Medline abstracts
  14. Henry CJ, Downing S, Rosenthal RC, et al. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs, Am J Vet Res 68:1246, 2007. Medline abstracts
  15. Betton GR, Gorman NT, Owen LN: Cell mediated cytotoxicity in dogs following systemic or local BCG treatment alone or in combination with allogeneic tumour cell lines, Eur J Cancer 15(5):745, 1979. Medline abstracts
  16. MacEwen EG, Patnaik AK, Harvey HJ, et al: Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum, Cancer Invest 4(5):397, 1986. Medline abstracts
  17. Thamm DH, Kurzman ID, King I, et al: Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: Phase I evaluation, Clin Cancer Res 11(13):4827, 2005. Medline abstracts
  18. Dow SW, Elmslie RE, Willson AP, et al: In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma, J Clin Invest 101(11):2406, 1998. Medline abstracts
  19. Thamm DH, Kurzman ID, MacEwen EG, et al: Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors, Cancer Immunol Immunother 52(8):473, 2003. Medline abstracts
  20. Suter SE, Chein MB, von Messling V, et al: In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma, Clin Cancer Res 11(4):1579, 2005. Medline abstracts
  21. Basak SK, Kiertscher SM, Harui A, et al: Modifying adenoviral vectors for use as gene-based cancer vaccines, Viral Immunol 17(2):182, 2004. Medline abstracts
  22. Harrop R, Carroll MW: Viral vectors for cancer immunotherapy, Front Biosci 11:804, 2006. Medline abstracts
  23. Fox LE, MacEwen EG, Kurzman ID, et al: Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma—a multicenter randomized double-blind study, Cancer Biother 10(2):125, 1995. Medline abstracts
  24. Kurzman ID, MacEwen EG, Rosenthal RC, et al: Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res 1(12):1595, 1995. Medline abstracts
  25. MacEwen EG, Kurzman ID, Helfand S, et al: Current studies of liposome muramyl tripeptide (CGP 19835A Lipid) therapy for metastasis in spontaneous tumors: a progress review, J Drug Target 2(5):391, 1994. Medline abstracts
  26. MacEwen EG, Kurzman ID, Vail DM, et al: Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor, Clin Cancer Res 5(12):4249, 1999. Medline abstracts
  27. Smith BW, Kurzman ID, Schultz KT, et al: Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells, Cancer Biother 8(2):137, 1993. Medline abstracts
  28. Teske E, Rutteman GR, Ingh TS, et al: Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma, Anticancer Res 18(2A):1015, 1998. Medline abstracts
  29. Hogge GS, Burkholder JK, Culp J, et al: Preclinical development of human granulocyte-macrophage colony-stimulating factor-transected melanoma cell vaccine using established canine cell lines and normal dogs, Cancer Gene Ther 6(1):26, 1999. Medline abstracts
  30. Gill VL, Bergman PJ, Baer K, et al: Use of imiquimod 5% cream (AldaraTM) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002-2005), Vet Comp Oncol 6:55, 2008. Medline abstracts
  31. Kamstock D, Guth A, Elmslie R, et al: Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma, Cancer Gene Ther 13(3):306, 2006. Medline abstracts
  32. Dow S, Elmslie R, Kurzman I, et al: Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases, Hum Gene Ther 16(8):937, 2005. Medline abstracts
  33. Funk J, Schmitz G, Failing K, et al: Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms, Cancer Immunol Immunother 54(1):87, 2005. Medline abstracts
  34. Helfand SC, Soergel SA, MacWilliams PS, et al: Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs, Cancer Immunol Immunother 39(2):84, 1994. Medline abstracts
  35. Quintin-Colonna F, Devauchelle P, Fradelizi D, et al: Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2, Gene Ther 3(12):1104, 1996. Medline abstracts
  36. Jourdier TM, Moste C, Bonnet MC, et al: Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2), Gene Ther 10(26):2126, 2003. Medline abstracts
  37. Khanna C, Waldrep JC, Anderson PM, et al: Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution, J Pharm Pharmacol 49(10):960, 1997. Medline abstracts
  38. Fujiwara H, Clark SC, Hamaoka T: Cellular and molecular mechanisms underlying IL-12-induced tumor regression, Ann NY Acad Sci 795:294, 1996. Medline abstracts
  39. Diab A, Cohen AD, Alpdogan O, et al: IL-15: targeting CD8+ T Cells for immunotherapy, Cytotherapy 7(1):23, 2005. Medline abstracts
  40. Dean GA, Barger A, Lavoy A: Cloning and expression of feline interleukin 15, Cytokine 29(2):77, 2005. Medline abstracts
  41. Tateyama S, Priosoeryanto BP, Yamaguchi R, et al: In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours, Res Vet Sci 59(3):275, 1995. Medline abstracts
  42. Whitley EM, Bird AC, Zucker KE, et al: Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines, Anticancer Res 15(3):923, 1995. Medline abstracts
  43. Alexander AN, Huelsmeyer MK, Mitzey A, et al: Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma, Cancer Immunol Immunother 55(4):433, 2006. Medline abstracts
  44. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, et al: Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen, J Vet Intern Med 19(1):56, 2005. Medline abstracts
  45. Jeglum KA: Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231, Vet Clin North Am Small Anim Pract 26(1):73, 1996. Medline abstracts
  46. Bergman PJ, Camps-Palau MA, McKnight JA, et al: Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center, Vaccine 24(21):4582, 2006. Medline abstracts
  47. Bergman PJ, McKnight J, Novosad A, et al: Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial, Clin Cancer Res 9(4):1284, 2003. Medline abstracts
  48. Liao JC, Gregor P, Wolchok JD, et al: Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma, Cancer Immun 6:8, 2006. Medline abstracts
  49. Peggs KS, Quezada SA, Korman AJ, et al: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy, Curr Opin Immunol 18(2):206, 2006. Medline abstracts
  50. Walter CU, Biller BJ, Lana SE, et al: Effects of chemotherapy on immune responses in dogs with cancer, J Vet Intern Med 20(2):342, 2006. Medline abstracts
  51. Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy, Cancer Res 65(18):8059, 2005. Medline abstracts